公开(公告)号：US20210061902A1

公开(公告)日：2021-03-04

申请号：US16925227

申请日：2020-07-09

申请人： Pfizer Inc. ,  The Regents of the University of California ,  The Board of Trustees of the Leland Stanford Junior University

发明人： Isaac J. RONDON ,  Natasha Crellin ,  Paul Bessette ,  Eleonora Trotta ,  Jeffrey A. Bluestone ,  Lauren K. Ely ,  Kenan C. Garcia

IPC分类号： C07K16/24

摘要： The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

公开(公告)号：US20200095334A1

公开(公告)日：2020-03-26

申请号：US15746305

申请日：2016-07-22

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  PFIZER INC.

发明人： Thomas MIKITA ,  Lauren K. ELY ,  Huilan GAO ,  Yun KIM ,  Isaac J. RONDON ,  Tovo DAVID ,  Shaun R. COUGHLIN

IPC分类号： C07K16/36

摘要： In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.

公开(公告)号：US20220119545A1

公开(公告)日：2022-04-21

申请号：US17292257

申请日：2019-11-07

申请人： Beth Israel Deaconess Medical Center ,  Pfizer Inc. ,  Cornell University

发明人： Lewis C. CANTLEY ,  Stephen P. SOLTOFF ,  Brooke M. EMERLING ,  George POULOGIANNIS ,  Cindy M. HODAKOSKI ,  Hui LIU ,  Irina APOSTOLOU ,  Brian Gaither BATES ,  Kimberly Ann MARQUETTE ,  Eric M. BENNETT ,  Lidia MOSYAK ,  Lioudmila G. TCHISTIAKOVA ,  Edward Christian ROSFJORD ,  Isaac J. RONDON ,  Chao Bai HUANG

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.

公开(公告)号：US20210403600A1

公开(公告)日：2021-12-30

申请号：US17355530

申请日：2021-06-23

申请人： THE REGENTS OF THE UNIVERSITY OF CALFORNIA ,  PFIZER INC.

发明人： Thomas MIKITA ,  Lauren K. ELY ,  Huilan GAO ,  Yun KIM ,  Isaac J. RONDON ,  Tovo DAVID ,  Shaun R. COUGHLIN

IPC分类号： C07K16/36

摘要： In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.